Cargando…

Do statins benefit low-risk population for primary prevention of atherosclerotic cardiovascular disease: A retrospective cohort study

The reported beneficial effects of statins on cardiovascular outcome based on risk assessment are inconsistent. Therefore, we investigated statin therapy effectiveness for the primary prevention of cardiovascular disease (CVD), according to the Korean Risk Prediction Model (KRPM). Subjects aged 40–7...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ryou, In Sun, Kim, Ju Young, Park, Hwa Yeon, Oh, Sohee, Kim, Sehun, Kim, Hwa Jung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9669657/ https://www.ncbi.nlm.nih.gov/pubmed/36405617 http://dx.doi.org/10.3389/fmed.2022.1024780

Ejemplares similares

Assessing potential population impact of statin treatment for primary prevention of atherosclerotic cardiovascular diseases in the USA: population-based modelling study
por: Yang, Quanhe, et al.
Publicado: (2017)

Statins for the primary prevention of cardiovascular disease: an overview of systematic reviews
por: Byrne, Paula, et al.
Publicado: (2019)

The Prevalence of Potential Prescribing Omissions for Antiplatelets and Statins in Older Adults With Atherosclerotic Cardiovascular Disease
por: Alshehri, Samah, et al.
Publicado: (2023)

Antioxidant Effects of Statins in Patients with Atherosclerotic Cerebrovascular Disease
por: Moon, Gyeong Joon, et al.
Publicado: (2014)

Association between CVDs and initiation and adherence to statin treatment in patients with newly diagnosed hypercholesterolaemia: a retrospective cohort study
por: Ryou, In Sun, et al.
Publicado: (2021)

Statin Use for Atherosclerotic Cardiovascular Disease Prevention Among Sexual Minority Adults
por: Guo, Yi, et al.
Publicado: (2020)

Cost‐effectiveness of statins for primary prevention of atherosclerotic cardiovascular disease among people living with HIV in the United States
por: Boettiger, David C, et al.
Publicado: (2021)

Multimorbidity and statin prescription for primary prevention of cardiovascular diseases: A cross-sectional study in general practice in France
por: Onaisi, Racha, et al.
Publicado: (2023)

Statins for primary cardiovascular prevention in the elderly
por: Pedro-Botet, Juan, et al.
Publicado: (2015)

Achievement of low-density lipoprotein cholesterol targets in Chinese patients with atherosclerotic cardiovascular disease after receiving statins and ezetimibe
por: Cheng, Yinchu, et al.
Publicado: (2022)

Statin/ezetimibe combination therapy vs statin monotherapy for carotid atherosclerotic plaque inflammation
por: Oh, Minyoung, et al.
Publicado: (2021)

Impact of China’s Low Centralized Medicine Procurement Prices on the Cost-Effectiveness of Statins for the Primary Prevention of Atherosclerotic Cardiovascular Disease
por: Wang, Miao, et al.
Publicado: (2020)

Effects of Race on Statin Prescribing for Primary Prevention With High Atherosclerotic Cardiovascular Disease Risk in a Large Healthcare System
por: Dorsch, Michael P., et al.
Publicado: (2019)

Clinical encounter length and initiation of statin therapy for primary prevention among adults with elevated atherosclerotic cardiovascular disease risk
por: Zheutlin, Alexander R., et al.
Publicado: (2022)

Statin Use and Eligibility for Primary Prevention of Atherosclerotic Cardiovascular Disease Among Adults at Borderline or Intermediate Risk in the United States
por: Hammond, Michael M., et al.
Publicado: (2023)

Risk‐benefit analysis of use of statins for primary prevention of cardiovascular disease in subjects without diabetes
por: Chan, Juliana CN
Publicado: (2013)

Older adult preferences regarding benefits and harms of statin and aspirin therapy for cardiovascular primary prevention()
por: Wang, Frances M., et al.
Publicado: (2023)

Applying the behavior change wheel to design de-implementation strategies to reduce low-value statin prescription in primary prevention of cardiovascular disease in primary care
por: Sanchez, Alvaro, et al.
Publicado: (2022)

Underuse of statins for secondary prevention of atherosclerotic cardiovascular disease events among ambulatory surgical patients
por: Schonberger, Robert B., et al.
Publicado: (2020)

Wildfire smoke exposure and cardiovascular disease—should statins be recommended to prevent cardiovascular events?
por: Vuorio, Alpo, et al.
Publicado: (2023)

Association between statin therapy and mortality in patients on dialysis after atherosclerotic cardiovascular diseases
por: Lee, Myunhee, et al.
Publicado: (2023)

Cardiovascular Imaging for the Primary Prevention of Atherosclerotic Cardiovascular Disease Events
por: Weber, Lauren A., et al.
Publicado: (2015)

Cross-sectional analysis of the prevalence and predictors of statin utilisation in Ireland with a focus on primary prevention of cardiovascular disease
por: Byrne, Paula, et al.
Publicado: (2018)

Commentary: Beyond 10-year risk: A cost-effectiveness analysis of statins for the primary prevention of cardiovascular disease
por: Shah, Aditya, et al.
Publicado: (2022)

High‐Intensity Statin Reduces the Risk of Mortality Among Chronic Liver Disease Patients With Atherosclerotic Cardiovascular Disease: A Population‐Based Cohort Study
por: Bea, Sungho, et al.
Publicado: (2023)

Comparisons of different indices of low muscle mass in relationship with cardiometabolic disorder
por: Kim, Ju Young, et al.
Publicado: (2019)

Author Correction: Comparisons of different indices of low muscle mass in relationship with cardiometabolic disorder
por: Kim, Ju Young, et al.
Publicado: (2020)

Survival Benefits of Statins for Primary Prevention: A Cohort Study
por: Gitsels, Lisanne A., et al.
Publicado: (2016)

Statins for atherosclerotic cardiovascular disease prevention in people living with HIV in Thailand: a cost‐effectiveness analysis
por: Boettiger, David C, et al.
Publicado: (2020)

Use of Aspirin and Statin as primary prevention for cardiovascular diseases
por: Alkhail, Bahaa Aba, et al.
Publicado: (2016)

Statins alone or polypill for primary prevention of cardiovascular diseases
por: Hasani-Ranjbar, Shirin, et al.
Publicado: (2016)

Do Changes in Innate Immunity Underlie the Cardiovascular Benefits of Exercise?
por: Chuong, Phillip, et al.
Publicado: (2019)

Net benefit of statins for primary prevention of cardiovascular disease in people 75 years or older: a benefit–harm balance modeling study
por: Yebyo, Henock G., et al.
Publicado: (2019)

Population Impact & Efficiency of Benefit‐Targeted Versus Risk‐Targeted Statin Prescribing for Primary Prevention of Cardiovascular Disease
por: Pletcher, Mark J., et al.
Publicado: (2017)

Association of Periodontitis with Atherosclerotic Cardiovascular Diseases: A Nationwide Population-based Retrospective Matched Cohort Study
por: Byon, Min-Ji, et al.
Publicado: (2020)

Assessment of Trends in Statin Therapy for Secondary Prevention of Atherosclerotic Cardiovascular Disease in US Adults From 2007 to 2016
por: Yao, Xiaoxi, et al.
Publicado: (2020)

The association of atherosclerotic cardiovascular disease and statin use with inflammation and treatment outcomes in tuberculosis
por: Chidambaram, Vignesh, et al.
Publicado: (2021)

Initiation rates of statin therapy for the primary prevention of cardiovascular disease: an assessment of differences between countries of the UK and between regions within England
por: O'Keeffe, Aidan G, et al.
Publicado: (2015)

The effect of telemedicine on secondary prevention of atherosclerotic cardiovascular disease: A systematic review and meta-analysis
por: Deng, Liangying, et al.
Publicado: (2022)

Statin therapy for preventing cardiovascular diseases in patients treated with tacrolimus after kidney transplantation
por: Han, Nayoung, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_htjai7gbbh20svvokr4utpsqbc